IPO Year: 2023
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/13/2024 | $28.00 | Outperform | Robert W. Baird |
| 6/6/2024 | $22.00 | Buy | H.C. Wainwright |
| 11/28/2023 | $20.00 | Overweight | JP Morgan |
| 11/28/2023 | $20.00 | Buy | Stifel |
| 11/28/2023 | $19.00 | Outperform | Leerink Partners |
| 11/28/2023 | $22.00 | Outperform | RBC Capital Mkts |
| 11/28/2023 | $23.00 | Buy | Chardan Capital Markets |
S-3/A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
S-3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
DEFA14A - Lexeo Therapeutics, Inc. (0001907108) (Filer)
SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SCHEDULE 13G - Lexeo Therapeutics, Inc. (0001907108) (Subject)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SCHEDULE 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)